Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

The main purpose of this study is to determine the safety and tolerability of PLN-74809 compared to a placebo, when taken daily for up to 12 weeks. The study also aims to determine how the body processes the study medication and assess any changes in the condition PSC.

If you have been diagnosed with primary sclerosing cholangitis (PSC), a rare, long-term liver disease affecting the bile ducts inside and outside the liver you could be eligible to participate in a research study by Pliant Therapeutics, investigating a medication named PLN-74809 for the treatment of PSC.